Analysts See $0.16 EPS for Repligen Corporation (RGEN) as of May, 3

April 16, 2018 - By Alice Reed

Repligen Corporation (NASDAQ:RGEN) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.26. That’s change of 0.05, from 2017Q3’s 1.31. 27 investors sold all, 46 reduced holdings as Repligen Corporation ratio is negative. 69 rose stakes while 23 funds acquired stakes. Funds hold 35.19 million shares thus 2.06% more from 2017Q3’s 34.48 million shares.
South Dakota Investment Council holds 0.05% of its capital in Repligen Corporation (NASDAQ:RGEN) for 58,700 shs. 25,325 are owned by Texas Permanent School Fund. Glenmede Co Na reported 1,801 shs stake. Tci Wealth Advsr Inc has invested 0% in Repligen Corporation (NASDAQ:RGEN). Gemmer Asset Limited Liability reported 84 shs or 0% of all its holdings. Stephens Mgmt Grp Ltd Limited Liability Company holds 0.76% or 912,362 shs. Comerica Bancorp reported 63,488 shs stake. Fmr holds 0% or 909,355 shs in its capital. Aperio Gru Lc invested in 0.01% or 33,063 shs. Federated Investors Inc Pa owns 860,560 shs for 0.09% of their capital. Citigroup accumulated 0% or 59,826 shs. Great West Life Assurance Can stated it has 49,181 shs. North Carolina-based Franklin Street Advisors Nc has invested 0.05% in Repligen Corporation (NASDAQ:RGEN). California-based Rice Hall James And Assocs Ltd Liability Corp has invested 0.09% in Repligen Corporation (NASDAQ:RGEN). Ny State Common Retirement Fund has invested 0% in Repligen Corporation (NASDAQ:RGEN).

Repligen Corporation had 3 insider sales and 0 buys since December 14, 2017. This’s net activity of $942,072. $322,445 worth of Repligen Corporation (NASDAQ:RGEN) was sold by Hunt Anthony. $169,792 worth of Repligen Corporation (NASDAQ:RGEN) was sold by RYAN THOMAS F JR on Thursday, March 8.

Repligen Corporation (NASDAQ:RGEN) is anticipated to reveal earnings on May, 3., Faxor reports. EPS of $0.16 is 6.67 % up from 2017’s $0.15 EPS. If the current EPS of $0.16 is accurate, RGEN’s profit could reach $6.97M. Wall Street forecasts -20.00 % negative EPS growth as of May, 3. On during the last trading session the stock increased $0.3 or 0.80%, reaching $37.65.Repligen Corporation has volume of 34 shares. Since April 16, 2017 RGEN has declined 0.29% and is downtrending. RGEN underperformed by 11.84% the S&P 500.

Repligen Corporation (NASDAQ:RGEN) Ratings Coverage

In total 5 analysts cover Repligen Corp (NASDAQ:RGEN). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. 80% are bullish. 5 are the (NASDAQ:RGEN)’s analyst reports since October 18, 2017 according to StockzIntelligence Inc. On Tuesday, December 5 the rating was initiated by J.P. Morgan with “Buy”. On Friday, December 8 the firm has “Buy” rating by Citigroup given. On Wednesday, October 18 the company was maintained by Jefferies.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The company has $1.64 billion market cap. It makes various forms of Protein A, a critical component used to purify antibody drugs.52.29 is the P/E ratio. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: